Arina V. Martynchyk

martynchyk1

Specialization: Clinical Oncology, Hematology

Experience specialty: 6 years

Qualifying Category: second

Certificates and licenses: medical doctor (2007), Certificate in Clinical Oncology (2009), Certificate in Hematology (2013)

The main directions of scientific and practical research: Lymphomas, Multiple Myeloma, FISH-diagnostics

Participation in conferences, seminars, symposia: International Conference on Malignant Lymphoma (Lugano, Switzerland), Leukaemia and Lymphoma (Ascona, Switzerland), COHEM etc.

Availability of awards, certificates, prizes: Fellowship in Russian Institute of Hematology and Transfusiology, Laboratory of Cytogenetic, S.Petersburg, Russia; Technology transfer fellowship in Laboratory of Experimental Oncology, Bellinzona, Switzerland, UICC grant (11.05.2011 – 13.06.2011); Certificate of attending Salzburg Seminars in Oncology (25.04-1.05.2010); First Certificate in English of Council of Europe Level B2; English Language Certificate of British Council Course in General English (Upper-Intermediate) with overall grade “A”; Certificate in Medical English; Professional exchange program of medical student in the University Hospital of Ferrara, Italy, 2007; Professional exchange program of medical student in the University Hospital of Linkoping, Sweden, 2005

Membership: ESMO (since 2010), UICC (since 2011), ESO (since 2011), EHA (since 2012)

A favorite expression (expression aphorism): Non progredi – est regredi

The presence of scientific publications:

Complications of chemotherapy in patients with oncologic and oncohematologic diseases / I.Kriachok, I.Tytorenko, O.Aleksik, O.Novosad, S.Lyalkin, E.Kuscheviy, A.Martynchyk, Y.Pastushenko // Health of Ukraine. – 2009. – V.1 / 1. – P. 34.
Complications of chemotherapy in patients with oncologic and oncohematologic diseases / I.Kriachok, I.Tytorenko, O.Aleksik, O.Novosad, S.Lyalkin, E.Kuscheviy, A.Martynchyk, Y.Pastushenko // Health of Ukraine. – 2009. – V.1 / 2. – P. 29.
Modern algorithms of treatment of patients with early stage Hodgkin’s lymphoma / I.Kryachok, A.Martynchyk, I.Tytorenko et al. // Ukrainian medical annals. – 2009. – V.4 (72) – VII / VIІI. – P.92-95.
Modern algorithms of treatment of patients with advanced Hodgkin’s lymphoma / I.Kryachok, A.Martynchyk, I.Tytorenko et al. // Ukrainian medical annals. – 2009. – V.5 (73) – IX / X. – P.76 – 79
Prognostic factors of clinical course of Hodgkin’s lymphoma: the present and the future / I.Kriachok, I.Tytorenko, O.Novosad, A. Martynchyk // Ukrainian medical annals. – 2009. -V.6 (74) – XІ / XІI. – P. 88 – 91.
Positron-emission tomography as a measure of effectiveness of the treatment of patients with lymphomas / I.Kriachok, A.Martynchyk, I.Tytorenko // Scientific newsletter. – 2009. – ISSN 1681-276X, V.4 (57). – P.114 – 116.
The method of detection of primary refractory low risk patients with non-hodgkin’s large B-cell lymphoma: Patent UA 51404, IPC A 61 10/00. / I.Kriachok, O.Aleksik, A.Martynchyk et al; National Cancer Institute (UA). Patent. – Application № 201001787; apply 19.02.2010; publish. 12.07.2010.
Use of Filgrastim in treatment of high risk patients with Hodgkin’s lymphomas / I.Kriachok, A.Martynchyk, I.Tytorenko et al. // Oncology. – 2010. – V.12 (1). – P. 81 – 85.
Anaemic syndrome in hematological diseases. Clinical recommendations, prevention and treatment / I.Kriachok, I.Tytorenko, A.Martynchyk et al. // Oncology. – 2010. – V.12 (1). – P. 87 – 89.
Hodgkin’s lymphoma: yesterday, today and tomorrow / I.Kriachok, I.Tytorenko, K.Filonenko, O.Aleksik, T.Kadnikova, H, Gubareva, O.Novosad, A.Martynchyk et al. // Oncology, Special Volume. – 2010. – P.53 – 60.
The treatment of patients with refractory forms of Hodgkin’s lymphomas / H.Hubareva, I.Kriachok, I.Tytorenko, O.Aleksyk, O.Novosad, T.Kadnikova, A.Martynchyk // Likarska sprava. – 2010. – V.1. – P. 115-118.
Thromboprophylaxis for Multiple Myeloma patients who receive Thalidomide-contained treatment / I.Kriachok, O.Novosad, K.Filonenko, I.Tytorenko, A.Martynchyk // The Conference “Jubilee scientific conference with international experts”, Lviv. – 2010. – P. 100 – 101.
Somatic, psychological and social rehabilitation of patients with lymphoproliferative diseases / I.Kriachok, A.Martynchyk, I.Tytorenko et al. // The Conference “Strategy and tactics spa rehabilitation of patients after treatment of cancer”, Myrgorod. – 2010.
BEACOPP-14 VS BEACOPP-ESC in patients with Hodgkin’s lymphoma from poor-prognosis group: preliminary results of prospective randomizer study / I.Kriachok, K.Filonenko, I.Tytorenko, O.Novosad, A.Martynchyk et al .// 15th Congress of the European Hematology Association. – 2010. – Abstract № 1366.
Clinical case of chronic lympocytic leukemia with plasmacytoid differentiation / A.Marynchyk, I.Kriachok, K.Filonenko, O.Novosad, E.Kuscheviy // COHEM, The 1st World Congress on controversies in hematology, “Program and abstracts”, Italy, Rome. – 2010. – P. 14.
The method of detection of primary refractory low risk patients with non-hodgkin’s large B-cell lymphoma: Patent UA 51404, IPC A 61 10/00. / I.Kriachok, O.Aleksik, A.Martynchyk et al; National Cancer Institute (UA). – Application № 201001787; apply 19.02.2010; publish. 12.07.2010.
The method of risk stratification of patients with small cell non-hodgkin’s lymphoma: Patent 59422 IPS A 61 10/00 / I.Kriachok, O.Aleksik, A. Martynchyk et al. National Cancer Institute (UA) – Application № 201 014 154; apply 06.12.2010 publish.10.05.2011.
The method of prognosis identification in low risk patients with early stage of Hodgkin’s lymphoma: Patent 64,942 IPS A 61 10/00 / I.Kriachok, A. Martynchyk et al. National Cancer Institute (UA) -apply 14.04.2011 publish.25.11.2011.
The method of prognosis identification in high risk patients with advanced stage of Hodgkin’s lymphoma: Patent 70508 IPS A 61 10/00 / I.Kriachok, O. Novosad, N.Khranovska, N.Svergun, I.Tytorenko, A. Martynchyk. National Cancer Institute (UA) -apply 23.12.2011 publish.11.06.2012.
Second line treatment in non-hodgkin’s lymphoma / I.Kriachok, E.Kuscheviy, T.Kadnikova, A.Martynchyk et al. // XII Congress of World Federation of Ukrainian Doctors Associations, Lviv. – 2010. – P. 531.
Positron-emission tomography as a measure of effectiveness of the treatment of patients with lymphomas. Updated // I.Kriachok, A.Martynchyk, E.Kuscheviy et al. // XII Congress of World Federation of Ukrainian Doctors Associations, Lviv. – 2010. – P. 532.
Polymorphism of GSTP1 gene and prognosis of Hodgkin’s lymphoma in Ukrainian individuals / N.Svergun, I.Kriachok, N.Khranovska, O.Novosad, I.Tytorenko, V.Pozur, T.Kadnikova, O.Aleksik, K.Filonenko, A .Martynchyk et al. // Annals of Oncology. – 2011. – Vol.2, Suppl.4 – P. 495.
BEACOPP-14 vs. BEACOPP-ESC. in patients with Hodgkin’s disease from poor-prognosis group: interim analisys of prospective randomized multicenter study / I.Kriachok, I.Tytorenko, K.Filonenko, O.Novosad, T.Kadnikova, A.Martynchyk et al. // Heamatologica. Abstract book. – 2011. – V.96 (S.2). – P. 324, # 0778
Treatment of young patients with diffuse large B-cell lymphomas / I.Kriachok, K. Filonenko, E.Aleksik, I.Tytorenko, A.Martynchyk et al .// Clinical Oncology, Special Edition. – 2011. – P. 165
Experience of treatment of MM with Thalidomide in Ukraine / O.Novosad, I.Kriachok, T.Kadnikova, E.Aleksik, I.Tytorenko, E.Kuschevoy, Y.Pastushenko, K.Filonenko, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 165
The value of GSTP1 detection in prognosis identification in course of Hodgkin’s lymphoma / N. Svergun, N.Khranovska, I.Kriachok, O.Novosad, I.Tytorenko, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 166.
Effectiveness of therapy with Rituximab in NHL patients / I.Kriachok, K.Filonenko, G.Gubareva, I.Tytorenko, O.Aleksik, T.Kadnikova, O.Novosad, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 165.
Modern imaging in measuring of effectiveness of treatment of NHL patients / T.Sycheva, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 167.
Treatment of NHL patients taking into account clinical and molecular factors of disease’s course / I.Kraichok, O.Aleksik, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 162.
The effectiveness of treatment of relapse and primary-refractory LH and NHL / I.Kriachok, E.Kuschevoy, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 163.
PET as unfavorable prognostic factor / I.Kriachok, A.Martynchyk // Clinical Oncology, Special Edition. – 2011. – P. 163.
Preliminary results of treatment of patients with high risk patients with LH / I.Kriachok, I.Tytorenko, O.Novosad, T.Kadnikova, K.Filonenko, A.Martynchyk // Clinical Oncology, Special Edition. – 2011. – P. 163.
Experience of Filgrastim use in treatment of high risk patients with LH / I.Kriachok, I.Tytorenko, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 163.
10-years experience of treatment of Hodgkin lymphoma: historical aspects / I.Kriachok, K.Filonenko, O.Novosad, I.Tytorenko, T.Kadnikova, A.Martynchyk et al. // Clinical Oncology, Special Edition. – 2011. – P. 163.
Efficacy of therapy with rituximab in patients with non-hodgkin’s lymphomas / I.Kriachok, K.Filonenko, A.Gubareva, I.Tytorenko,, O.Novosad, T.Kadnikova, E.Aleksik, A.Martynchyk et al. // Likarska sprava. – 2011. – V.1-2. – P. 118-121.
Treatment of patients with relapsed and refractory Hodgkin’slymphoma. The role of high dose chemotherapy and stem cell transplantation / E. Kuschevyy, І.A. Kriachok, A.V. Martynchyk et al. // Clinical Oncology, – 2011. – Vol.1 – P. 78-88.
The experience of treatment of patients with relapsed and refractory lymphoma with salvage therapy / / І.A. Kriachok, E. Kuschevyy, A.V. Martynchyk et al. // Clinical Oncology, – 2011. – Vol.2 – P. 62-66.
Modern approaches to the first line treatment and modern world trends of Diffuse Large B-cell lymphoma / І.A. Kriachok, A.V. Martynchyk et al .// Clinical Oncology, – 2011. – Vol.3 – P. 76-80.
Therapy efficacy in patients with Non-Hodgkin’s Lymphomas with rituximab / І.A. Kriachok, K.S. Filonenko, G.O. Gubareva, І.B. Titorenko, OM Alexik, T.V. Kadnikova, OI Novosad, A.V. Martinchik et al .// Clinical Oncology, – 2011. – Vol.3 – P. 81-84.
The therapy of patients with DLBCL: world experience in Ukrainian medicine / І.A. Kriachok, K.S. Filonenko, OM Alexik, І.B. Titorenko, A.V. Martinchik // Clinical Oncology, – 2011. – Vol.4 – P. 82-87.
PET and CT in assessment of efficacy of treatment of patients with lymphoma / I.Kriachok, I.Tytorenko, T.Sychova, E.Aleksik, T.Kadnikova, A.Martynchyk et al. / Oncology, – 2012. – Vol.12 – P. 53-60.
The influence of GSTP1 A313G polymorphism on susceptibility, chemotherapy-related toxicity and prognosis of Hodgkin’s lymphoma in Ukrainian patients / I.Kriachok, N.Khranovska, N.Svergun, K.Filonenko, I.Tytorenko, A.Martynchyk et al. // Biopolimers and Cell, – 2012. – Vol.28 (1) – P. 56-61.
Biological factors of Hodgkin’s lymphoma prognosis (review) / NM Svergun, N.M. Khranovska, I.A. Kriachok, O.I. Novosad, I.B. Tytorenko, A.V. Martynchik et al. // Clinical Oncology, – 2012. – Vol.6 – P. 101-108.
Ukrainian experience in the use of thalidomide in the treatment of multiple myeloma / O.Novosad, Y.Stepanishina, I.Kriachok, T.Kadnikova, E.Aleksik, I.Tytorenko, E.Kuschevoy, Y.Pastushenko, K.Filonenko, A.Martynchyk et al. // COHEM, Program and abstracts, – P-8.
Secondary pancreatic involvement by diffuse large B-cell lymphoma presenting as acute pancreatitis / A. Martynchyk et al. // Oncology Hematology. – Suppl. European School of Oncology – Educational Cancer Convention Lugano. – S.21, OR33.
Primary CNS Lymphomas: from scientific researches to daily practice / I.A. Kriachok, K.S. Filonenko, E.V. Kushchevoy, I.B. Titorenko, T.V. Kadnikova, EM Aleksyk, A.V. Martynchyk // Clinical Oncology, – 2012. – Vol.6 – P. 91-100.
New approaches to diagnosis and treatment of lymphomas. Review of international conferences / I.A. Kriachok, A.V. Martynchyk et al. // Clinical Oncology, – 2012. – Vol.5 – P. 84-94.
What’s new in hematooncology? (Review of the last approaches to the diagnosis and treatment of lymphomas) / I.A. Kriachok, K.S. Filonenko, A.V. Martynchyk et al. // Clinical Oncology, – 2012. – Vol.7 – P. 1-3.
Telemedicine in diagnosis of oncologic and oncohematologic diseases / A.Martynchyk et al. // Ukrainian journal of telemedicine and medical telematic, 2012. – Vol.1. – P.13.
Genetic abnormalities in patients with multiple myeloma, their influence to disease pathogenesis and prognosis / A.Martynchyk, I.Kriachok // Clinical Oncology, – 2012. – Vol.8 – P.
Review of third international conference “Modern approaches to the diagnosis and treatment of lymphomas”, Kyiv, 18-19 October, 2012 / A.Martynchyk, I.Kriachok, et al. // Clinical Oncology, – 2012. – Vol.8 – P.101-109
BEACOPP-14 vs BEACOPP-esc in patients with Hodgkin’s lymphoma from poor-prognosis group: analisys of prospective randomized multicenter trial / IA Kryachok, O. I. Novosad, I.B. Tytorenko, T.V. Kadnikova, A.V. Martynchyk, et al. // Clinical Oncology, – 2012. – Vol.8 – P. 108-112
Cytomegalovirus infection in hematology and oncology patients receiving cytotoxic therapy (review and case report) / EV Kushchevyy, I.A. Kryachok, I.A. Stepanishyna, A.V. Martyncyk, K.S. Filonenko // Clinical Oncology, – 2013. – Vol.2 – P.104-107
Telemedicine in diagnostic of oncohematological malignancies. “IPath” project / A.V. Martyncyk, S.A. Antonuk, E.V. Kushchevyy // Clinical Oncology, – 2013. – Vol.2 – P.13
Neutropenia treatment in high risk patients with Hodgkin lymphoma / IA Stepanishyna, I.B. Tytorenko, O. I. Novosad, A.V. Martynchyk, et al. // Clinical Oncology, – 2013. – Vol.2 – P. 23
Necessity of routine computed tomography after the end of the lymphoma treatment / IA Kriachok., K.S. Filonenko, A.V. Martynchyk, E.V. Kushchevoy // Clinical Oncology, – 2013. – Vol.3 – P. 24
Glutathione S-transferase genotypes influence to prognosis of diffuse large B-cell lymphoma / O.Novosad, N.Svergun, A.Martynchyk et al. // Haematologica, 18th Congress of European Hematology Association. – 2013. – P. 632
Secondary tumors in patients after lymphoma treatment / I.Kriachok, A.Martynchyk et al. // The European Cancer Congress, – 2013. – P. 450.
Gene expression of activating transcription factor 5 as a predictor of survival in germinal cell diffuse large B-cell lymphoma / A.Martynchyk, I.Kriachok // Experimental Oncology, – 2013. – Vol.35 (2). – P. 141.
The method of treatment of high risk patients with Hodgkins lymphoma: Patent 82,393 IPS A 61 10/00 / I.Kriachok, A. Martynchyk et al. National Cancer Institute (UA) -apply 14.03.2013 publish.27.07.2013.
The method of prognosis identification for patients with DLBCL: Patent 85,576 IPS A 61 10/00 / I.Kriachok, A. Martynchyk et al. National Cancer Institute (UA) -apply 24.05.2013 publish.25.11.2013.

Facebook
Twitter